Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.

Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR, Loeb AL, Chapple CR.

Neurology. 2013 Aug 27;81(9):841-8. doi: 10.1212/WNL.0b013e3182a2ca4d. Epub 2013 Jul 26.

2.

Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.

Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P.

Neurourol Urodyn. 2013 Mar;32(3):242-9. doi: 10.1002/nau.22293. Epub 2012 Sep 10.

PMID:
22965657
3.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
4.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.

Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.

PMID:
23608668
5.

OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.

Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Patel VD, Zhou J, Thompson C, Kowalski JW.

Eur Urol. 2012 Jul;62(1):148-57. doi: 10.1016/j.eururo.2012.03.005. Epub 2012 Mar 14.

PMID:
22464310
6.

OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.

Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert KD, Brin MF, Jenkins B, Thompson C, Lam W, Heesakkers J, Haag-Molkenteller C.

Adv Ther. 2013 Sep;30(9):819-33. doi: 10.1007/s12325-013-0054-z. Epub 2013 Sep 27. Erratum in: Adv Ther. 2014 Feb;31(2):242.

7.

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.

Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C.

Neurourol Urodyn. 2013 Nov;32(8):1109-15. doi: 10.1002/nau.22376. Epub 2013 Feb 6.

8.

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C.

J Urol. 2012 Jun;187(6):2131-9. doi: 10.1016/j.juro.2012.01.125. Epub 2012 Apr 12.

PMID:
22503020
9.

An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.

Apostolidis A, Thompson C, Yan X, Mourad S.

World J Urol. 2013 Dec;31(6):1469-74. doi: 10.1007/s00345-012-0984-0. Epub 2012 Nov 18.

PMID:
23160758
10.

Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.

Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD.

Clin Ther. 2013 Apr;35(4):414-24. doi: 10.1016/j.clinthera.2013.02.020. Epub 2013 Mar 20.

PMID:
23522658
11.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group..

J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.

PMID:
23246476
12.
13.

Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.

Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, Thompson C, Li D, Haag-Molkenteller C.

Urology. 2013 Mar;81(3):491-7. doi: 10.1016/j.urology.2012.11.010. Epub 2013 Jan 3.

14.

Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.

Brubaker L, Gousse A, Sand P, Thompson C, Patel V, Zhou J, Jenkins B, Sievert KD.

Int Urogynecol J. 2012 Aug;23(8):1017-25. doi: 10.1007/s00192-011-1655-1. Epub 2012 Jan 25.

PMID:
22273813
15.

Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).

Cruz F, Nitti V.

Neurourol Urodyn. 2014 Jul;33 Suppl 3:S26-31. doi: 10.1002/nau.22630. Review.

PMID:
25042140
16.

Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.

Everaert K, Gruenenfelder J, Schulte-Baukloh H, Egerdie RB, Khalaf K, Joshi M, Ni Q, Sussman D.

Int J Urol. 2015 Dec;22(12):1131-7. doi: 10.1111/iju.12912. Epub 2015 Sep 22.

17.

Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.

Gamé X, Khan S, Panicker JN, Kalsi V, Dalton C, Elneil S, Hamid R, Dasgupta P, Fowler CJ.

BJU Int. 2011 Jun;107(11):1786-92. doi: 10.1111/j.1464-410X.2010.09791.x. Epub 2010 Oct 29.

18.

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.

Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, Xiangrong D, Liling Z, Maping H, Qingqing L, Qiuling L, Jiebing H, Tanghai H.

Spinal Cord. 2016 Jan;54(1):46-50. doi: 10.1038/sc.2015.143. Epub 2015 Aug 11.

PMID:
26261074
20.

The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.

Chen YC, Kuo HC.

Neurourol Urodyn. 2014 Jan;33(1):129-34. doi: 10.1002/nau.22395. Epub 2013 Mar 12.

PMID:
23494629

Supplemental Content

Support Center